Skip to main content


Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 4

MACE in the overall population by presence or absence of CV risk factors. n is the number of patients with an event; N is the number of patients in treatment group. CHD coronary heart disease, CI confidence interval, CV cardiovascular, CTRL control, DAPA dapagliflozin, eGFR estimated glomerular filtration rate, HR hazard ratio, Hx history, MACE major adverse cardiovascular events (CV death, myocardial infarction and stroke), p–y = patient–years

Back to article page